Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 2/2021

24.08.2020 | Original Article

Immunogenic necroptosis in the anti-tumor photodynamic action of BAM-SiPc, a silicon(IV) phthalocyanine-based photosensitizer

verfasst von: Ying Zhang, Ying-Kit Cheung, Dennis K. P. Ng, Wing-Ping Fong

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Photodynamic therapy (PDT) is an anti-tumor modality which employs three individually non-toxic substances, including photosensitizer, light and oxygen, to produce a toxic effect. Besides causing damage to blood vessels that supply oxygen and nutrients to the tumor and killing the tumor by a direct cytotoxic effect, PDT has also been known to trigger an anti-tumor immune response. For instance, our previous study showed that PDT with BAM-SiPc, a silicon(IV) phthalocyanine based-photosensitizer, can not only eradicate the mouse CT26 tumor cells in a Balb/c mouse model, but also protect the mice against further re-challenge of the tumor cells through an immunomodulatory mechanism. To understand more about the immune effect, the biochemical actions of BAM-SiPc-PDT on CT26 cells were studied in the in vitro system. It was confirmed that the PDT treatment could induce immunogenic necroptosis in the tumor cells. Upon treatment, different damage-associated molecular patterns were exposed onto the cell surface or released from the cells. Among them, calreticulin was found to translocate to the cell membrane through a pathway similar to that in chemotherapy. The activation of immune response was also demonstrated by an increase in the expression of different chemokines.
Literatur
1.
Zurück zum Zitat Preise D, Oren R, Glinert I, Kalchenko V, Jung S, Scherz A, Salomon Y (2009) Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother 58(1):71–84PubMedCrossRef Preise D, Oren R, Glinert I, Kalchenko V, Jung S, Scherz A, Salomon Y (2009) Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity. Cancer Immunol Immunother 58(1):71–84PubMedCrossRef
2.
Zurück zum Zitat Fong WP, Yeung HY, Lo PC, Ng DKP (2014) Photodynamic therapy. In: Ho AHP, K. D., Somekh MG, (eds) Handbook of photonics for biomedical engineering. Springer, Dordrecht, pp 657–681 Fong WP, Yeung HY, Lo PC, Ng DKP (2014) Photodynamic therapy. In: Ho AHP, K. D., Somekh MG, (eds) Handbook of photonics for biomedical engineering. Springer, Dordrecht, pp 657–681
3.
Zurück zum Zitat Yeung HY, Lo PC, Ng DK, Fong WP (2017) Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model. Cell Mol Immunol 14(2):223–234PubMedCrossRef Yeung HY, Lo PC, Ng DK, Fong WP (2017) Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model. Cell Mol Immunol 14(2):223–234PubMedCrossRef
4.
Zurück zum Zitat Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72CrossRefPubMed Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72CrossRefPubMed
5.
Zurück zum Zitat Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1(2):112–119PubMedCrossRef Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, Cuny GD, Mitchison TJ, Moskowitz MA, Yuan J (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol 1(2):112–119PubMedCrossRef
6.
Zurück zum Zitat Krysko O, Aaes T, Kagan VE, D'Herde K, Bachert C, Leybaert L, Vandenabeele P, Krysko DV (2017) Necroptotic cell death in anti-cancer therapy. Immunol Rev 280(1):207–219PubMedCrossRef Krysko O, Aaes T, Kagan VE, D'Herde K, Bachert C, Leybaert L, Vandenabeele P, Krysko DV (2017) Necroptotic cell death in anti-cancer therapy. Immunol Rev 280(1):207–219PubMedCrossRef
7.
Zurück zum Zitat Liu X, Shi F, Li Y, Yu X, Peng S, Li W, Luo X, Cao Y (2016) Post-translational modifications as key regulators of TNF-induced necroptosis. Cell Death Dis 7(7):e2293PubMedPubMedCentralCrossRef Liu X, Shi F, Li Y, Yu X, Peng S, Li W, Luo X, Cao Y (2016) Post-translational modifications as key regulators of TNF-induced necroptosis. Cell Death Dis 7(7):e2293PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123(2):321–334PubMedCrossRef Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123(2):321–334PubMedCrossRef
9.
Zurück zum Zitat Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61PubMedCrossRef Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13(1):54–61PubMedCrossRef
10.
Zurück zum Zitat Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28(5):578–590PubMedPubMedCentralCrossRef Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P, Yuan J, Zitvogel L, Madeo F, Williams DB, Kroemer G (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28(5):578–590PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, Delrue I, Taminau J, Wiernicki B, De Groote P, Garg AD, Leybaert L, Grooten J, Bertrand MJ, Agostinis P, Berx G, Declercq W, Vandenabeele P, Krysko DV (2016) Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 15(2):274–287PubMedCrossRef Aaes TL, Kaczmarek A, Delvaeye T, De Craene B, De Koker S, Heyndrickx L, Delrue I, Taminau J, Wiernicki B, De Groote P, Garg AD, Leybaert L, Grooten J, Bertrand MJ, Agostinis P, Berx G, Declercq W, Vandenabeele P, Krysko DV (2016) Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 15(2):274–287PubMedCrossRef
12.
Zurück zum Zitat Lin J, Kumari S, Kim C, Van TM, Wachsmuth L, Polykratis A, Pasparakis M (2016) RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation. Nature 540(7631):124–128PubMedPubMedCentralCrossRef Lin J, Kumari S, Kim C, Van TM, Wachsmuth L, Polykratis A, Pasparakis M (2016) RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation. Nature 540(7631):124–128PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G (2014) Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 21(1):59–68PubMedCrossRef Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G (2014) Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 21(1):59–68PubMedCrossRef
14.
Zurück zum Zitat Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168(7):3195–3204CrossRefPubMed Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, Luster AD (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168(7):3195–3204CrossRefPubMed
15.
Zurück zum Zitat Yuan J, Liu Z, Lim T, Zhang H, He J, Walker E, Shier C, Wang Y, Su Y, Sall A, McManus B, Yang D (2009) CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 104(5):628–638PubMedCrossRef Yuan J, Liu Z, Lim T, Zhang H, He J, Walker E, Shier C, Wang Y, Su Y, Sall A, McManus B, Yang D (2009) CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res 104(5):628–638PubMedCrossRef
16.
Zurück zum Zitat Williams SA, Harata-Lee Y, Comerford I, Anderson RL, Smyth MJ, McColl SR (2010) Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer 9:250PubMedPubMedCentralCrossRef Williams SA, Harata-Lee Y, Comerford I, Anderson RL, Smyth MJ, McColl SR (2010) Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer 9:250PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT (1998) A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391(6669):799–803PubMedCrossRef Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT (1998) A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 391(6669):799–803PubMedCrossRef
18.
Zurück zum Zitat Garg AD, Vandenherk L, Fang S, Fasche T, Van Eygen S, Maes J, Van Woensel M, Koks C, Vanthillo N, Graf N, de Witte P, Van Gool S, Salven P, Agostinis P (2017) Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ 24(5):832–843PubMedPubMedCentralCrossRef Garg AD, Vandenherk L, Fang S, Fasche T, Van Eygen S, Maes J, Van Woensel M, Koks C, Vanthillo N, Graf N, de Witte P, Van Gool S, Salven P, Agostinis P (2017) Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ 24(5):832–843PubMedPubMedCentralCrossRef
19.
Zurück zum Zitat Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC (2019) Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity. Biochim Biophys Acta Rev Cancer 1872(2):188308PubMedCrossRef Donohoe C, Senge MO, Arnaut LG, Gomes-da-Silva LC (2019) Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity. Biochim Biophys Acta Rev Cancer 1872(2):188308PubMedCrossRef
20.
Zurück zum Zitat Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B (2020) Nanocarriers in photodynamic therapy-in vitro and in vivo studies. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12(3):e1509PubMedCrossRef Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz B (2020) Nanocarriers in photodynamic therapy-in vitro and in vivo studies. Wiley Interdiscip Rev Nanomed Nanobiotechnol 12(3):e1509PubMedCrossRef
21.
Zurück zum Zitat Lo PC, Huang JD, Cheng DY, Chan EY, Fong WP, Ko WH, Ng DK (2004) New amphiphilic silicon(IV) phthalocyanines as efficient photosensitizers for photodynamic therapy: synthesis, photophysical properties, and in vitro photodynamic activities. Chemistry 10(19):4831–4838PubMedCrossRef Lo PC, Huang JD, Cheng DY, Chan EY, Fong WP, Ko WH, Ng DK (2004) New amphiphilic silicon(IV) phthalocyanines as efficient photosensitizers for photodynamic therapy: synthesis, photophysical properties, and in vitro photodynamic activities. Chemistry 10(19):4831–4838PubMedCrossRef
22.
Zurück zum Zitat Leung SC, Lo PC, Ng DK, Liu WK, Fung KP, Fong WP (2008) Photodynamic activity of BAM-SiPc, an unsymmetrical bisamino silicon(IV) phthalocyanine, in tumour-bearing nude mice. Br J Pharmacol 154(1):4–12PubMedPubMedCentralCrossRef Leung SC, Lo PC, Ng DK, Liu WK, Fung KP, Fong WP (2008) Photodynamic activity of BAM-SiPc, an unsymmetrical bisamino silicon(IV) phthalocyanine, in tumour-bearing nude mice. Br J Pharmacol 154(1):4–12PubMedPubMedCentralCrossRef
23.
Zurück zum Zitat Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, Annaert W, Golab J, de Witte P, Vandenabeele P, Agostinis P (2012) A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31(5):1062–1079PubMedPubMedCentralCrossRef Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, Rubio N, Firczuk M, Mathieu C, Roebroek AJ, Annaert W, Golab J, de Witte P, Vandenabeele P, Agostinis P (2012) A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 31(5):1062–1079PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Cao C, Han Y, Ren Y, Wang Y (2009) Mitoxantrone-mediated apoptotic B16–F1 cells induce specific anti-tumor immune response. Cell Mol immunol 6(6):469–475PubMedPubMedCentralCrossRef Cao C, Han Y, Ren Y, Wang Y (2009) Mitoxantrone-mediated apoptotic B16–F1 cells induce specific anti-tumor immune response. Cell Mol immunol 6(6):469–475PubMedPubMedCentralCrossRef
25.
Zurück zum Zitat Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17(2):97–111PubMedCrossRef Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G (2017) Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 17(2):97–111PubMedCrossRef
26.
Zurück zum Zitat Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Hoti N, Castanares M, Wu M (2007) Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell Signal 19(10):2056–2067PubMedCrossRef Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Hoti N, Castanares M, Wu M (2007) Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase domain. Cell Signal 19(10):2056–2067PubMedCrossRef
27.
Zurück zum Zitat Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR (2011) Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471(7338):363–367PubMedPubMedCentralCrossRef Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, Hakem R, Salvesen GS, Green DR (2011) Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471(7338):363–367PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Takemura R, Takaki H, Okada S, Shime H, Akazawa T, Oshiumi H, Matsumoto M, Teshima T, Seya T (2015) PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol Res 3(8):902–914PubMedCrossRef Takemura R, Takaki H, Okada S, Shime H, Akazawa T, Oshiumi H, Matsumoto M, Teshima T, Seya T (2015) PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-mediated tumor elimination in vivo. Cancer Immunol Res 3(8):902–914PubMedCrossRef
29.
Zurück zum Zitat Yan G, Zhao H, Zhang Q, Zhou Y, Wu L, Lei J, Wang X, Zhang J, Zhang X, Zheng L, Du G, Xiao W, Tang B, Miao H, Li Y (2018) A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis. Cancer Res 78(19):5586–5599PubMedCrossRef Yan G, Zhao H, Zhang Q, Zhou Y, Wu L, Lei J, Wang X, Zhang J, Zhang X, Zheng L, Du G, Xiao W, Tang B, Miao H, Li Y (2018) A RIPK3-PGE2 circuit mediates myeloid-derived suppressor cell-potentiated colorectal carcinogenesis. Cancer Res 78(19):5586–5599PubMedCrossRef
30.
Zurück zum Zitat Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, Zitvogel L, Kepp O, Kroemer G (2016) Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology 5(6):e1149673PubMedPubMedCentralCrossRef Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, Zitvogel L, Kepp O, Kroemer G (2016) Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology 5(6):e1149673PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Coupienne I, Fettweis G, Rubio N, Agostinis P, Piette J (2011) 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. Photochem Photobiol Sci 10(12):1868–1878PubMedCrossRef Coupienne I, Fettweis G, Rubio N, Agostinis P, Piette J (2011) 5-ALA-PDT induces RIP3-dependent necrosis in glioblastoma. Photochem Photobiol Sci 10(12):1868–1878PubMedCrossRef
32.
Zurück zum Zitat Miki Y, Akimoto J, Moritake K, Hironaka C, Fujiwara Y (2015) Photodynamic therapy using talaporfin sodium induces concentration-dependent programmed necroptosis in human glioblastoma T98G cells. Lasers Med Sci 30(6):1739–1745PubMedCrossRef Miki Y, Akimoto J, Moritake K, Hironaka C, Fujiwara Y (2015) Photodynamic therapy using talaporfin sodium induces concentration-dependent programmed necroptosis in human glioblastoma T98G cells. Lasers Med Sci 30(6):1739–1745PubMedCrossRef
33.
Zurück zum Zitat Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188(12):2349–2356PubMedPubMedCentralCrossRef Pike SE, Yao L, Jones KD, Cherney B, Appella E, Sakaguchi K, Nakhasi H, Teruya-Feldstein J, Wirth P, Gupta G, Tosato G (1998) Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188(12):2349–2356PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat Persano L, Crescenzi M, Indraccolo S (2007) Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 28(1):87–114PubMedCrossRef Persano L, Crescenzi M, Indraccolo S (2007) Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 28(1):87–114PubMedCrossRef
35.
Zurück zum Zitat Udartseva OO, Zhidkova OV, Ezdakova MI, Ogneva IV, Andreeva ER, Buravkova LB, Gollnick SO (2019) Low-dose photodynamic therapy promotes angiogenic potential and increases immunogenicity of human mesenchymal stromal cells. J Photochem Photobiol B 199:111596PubMedCrossRef Udartseva OO, Zhidkova OV, Ezdakova MI, Ogneva IV, Andreeva ER, Buravkova LB, Gollnick SO (2019) Low-dose photodynamic therapy promotes angiogenic potential and increases immunogenicity of human mesenchymal stromal cells. J Photochem Photobiol B 199:111596PubMedCrossRef
36.
Zurück zum Zitat Zhang Y, Ng DKP, Fong WP (2019) Antitumor immunity induced by the photodynamic action of BAM-SiPc, a silicon (IV) phthalocyanine photosensitizer. Cell Mol Immunol 16(7):676–678PubMedPubMedCentralCrossRef Zhang Y, Ng DKP, Fong WP (2019) Antitumor immunity induced by the photodynamic action of BAM-SiPc, a silicon (IV) phthalocyanine photosensitizer. Cell Mol Immunol 16(7):676–678PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Garg AD, Krysko DV, Vandenabeele P, Agostinis P (2012) Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 61(2):215–221PubMedCrossRef Garg AD, Krysko DV, Vandenabeele P, Agostinis P (2012) Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother 61(2):215–221PubMedCrossRef
39.
Zurück zum Zitat Vogel C, Marcotte EM (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13(4):227–232PubMedPubMedCentralCrossRef Vogel C, Marcotte EM (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13(4):227–232PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Liu Y, Beyer A, Aebersold R (2016) On the dependency of cellular protein levels on mRNA abundance. Cell 165(3):535–550PubMedCrossRef Liu Y, Beyer A, Aebersold R (2016) On the dependency of cellular protein levels on mRNA abundance. Cell 165(3):535–550PubMedCrossRef
41.
Zurück zum Zitat Zhu K, Liang W, Ma Z, Xu D, Cao S, Lu X, Liu N, Shan B, Qian L, Yuan J (2018) Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis 9(5):500PubMedPubMedCentralCrossRef Zhu K, Liang W, Ma Z, Xu D, Cao S, Lu X, Liu N, Shan B, Qian L, Yuan J (2018) Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis 9(5):500PubMedPubMedCentralCrossRef
43.
Zurück zum Zitat Mollica Poeta V, Massara M, Capucetti A, Bonecchi R (2019) Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol 10:379PubMedPubMedCentralCrossRef Mollica Poeta V, Massara M, Capucetti A, Bonecchi R (2019) Chemokines and chemokine receptors: new targets for cancer immunotherapy. Front Immunol 10:379PubMedPubMedCentralCrossRef
Metadaten
Titel
Immunogenic necroptosis in the anti-tumor photodynamic action of BAM-SiPc, a silicon(IV) phthalocyanine-based photosensitizer
verfasst von
Ying Zhang
Ying-Kit Cheung
Dennis K. P. Ng
Wing-Ping Fong
Publikationsdatum
24.08.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 2/2021
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02700-x

Weitere Artikel der Ausgabe 2/2021

Cancer Immunology, Immunotherapy 2/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.